Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

RFS-2000 (now rubitecan) advances in clinical trials in over 10 tumor types

May 14, 1999

IntraDose NDA to receive fast track review by FDA

May 14, 1999

Glaxo reports kinase inhibitors especially useful for chemotherapy-induced alopecia

May 14, 1999

Microtubule disruption by T-138067 produces potent anticancer activity in MDR tumors

May 14, 1999

Exisulind leads to lower PSA levels according to interim phase II/III data

May 13, 1999

AstraZeneca launches Casodex 80 mg in Japan for treatment of prostate cancer

May 12, 1999

POH enters additional phase II trials

May 12, 1999

Trimelamol analogue available for licensing from CRCT

May 12, 1999

Isis initiates phase II clinical trials of ISIS-2503

May 11, 1999

Non-cysteine-containing FTase inhibitors from Abbott with good oral bioavailability

May 11, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...